Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Crohn’s Disease: One Gene Copy Too Few Leads to Weakened Defense

No. 59 | 17/07/2006 | by (Koh)

Patients with Crohn’s disease of the colon have one copy less than healthy persons of the beta-defensin 2 gene, a gene coding for an important defense molecule of the body. An international research team comprising scientists of the Robert Bosch Hospital in Stuttgart and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg have discovered a possible cause of the chronic inflammations.

Crohn’s disease (CD) is a chronic inflammatory disease of the intestinal tract affecting most commonly the lower part of the small bowel, called the ileum, and the colon. The cause of the disease is unknown; genetic and environmental factors have been suggested to play a role.

Defensins are part of the arsenal of defense weapons used by the human immune system. The peptides consist of only about 30 protein building blocks and act like our body’s own antibiotics that protect the mucous membranes from bacterial invasion. Patients with Crohn’s disease of the colon (colonic CD) have a lower level of beta-defensins in the mucous membranes. In a collaborative research project headed by Dr. Klaus Fellermann and Professor Eduard F. Stange, Robert Bosch Hospital, Stuttgart, researchers from the German Cancer Research Center and the Universities of Vienna and Davis, California, have now discovered that the number of defensin gene copies has a crucial influence on the development of the disease.

Defensin genes are arranged in nests, called clusters, on chromosome 8. The number of clusters varies considerably across the population; this is technically called a polymorphism. The research team has now shown that patients with colonic CD have on average only three copies of the gene encoding beta-defensin 2, whereas healthy control persons as well as patients with small bowel CD or ulcerative colitis, another inflammatory bowel disease, have an average of four copies of this gene per cell.

The researchers showed that a lower number of gene copies is indeed associated with reduced production of the endogenous antibiotic, which explains the known low defensin level. They presume that this causes the defense of the intestinal mucous membrane to become porous so that bacteria can attach to and invade the mucous membrane, which leads to the typical inflammatory hot spots of Crohn’s disease.

The disease, which is named after American physician Dr. Burrill Bernhard Crohn, is characterized by recurring episodes of active disease. It affects approximately 150,000 people in Germany; five new cases per 100,000 inhabitants are diagnosed each year. There has been a substantial rise in incidence rates in recent years. Patients suffering from Crohn’s disease also have an elevated risk of developing bowel cancer.

Klaus Fellermann, Daniel E. Stange, Elke Schaeffeler, Hartmut Schmalzl, Jan Wehkamp, Charles L. Bevins, Walter Reinisch, Alexander Teml, Mattias Schwab, Peter Lichter, Bernhard Radlwimmer and Eduard F. Stange: A chromosome 8 gene cluster with low human beta-defensin copy number predisposes to Crohn’s disease of the colon. The American Journal of Human Genetics, e-pub ahead of print

DOI: http://www.journals.uchicago.edu/AJHG/journal/issues/v79n3/43501/brief/43501.abstract.html

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS